

# Orphanet Journal of Rare Diseases

## Genetic, clinical and biochemical characterization of a large cohort of patients with hyaline fibromatosis syndrome --Manuscript Draft--

<b>Manuscript Number:</b>	OJRD-D-18-00535R1
<b>Full Title:</b>	Genetic, clinical and biochemical characterization of a large cohort of patients with hyaline fibromatosis syndrome
<b>Article Type:</b>	Research
<b>Funding Information:</b>	
<b>Abstract:</b>	<p>Background: Hyaline fibromatosis syndrome (HFS) is a rare clinical condition in which bi-allelic variants in ANTXR2 are associated with extracellular hyaline deposits. It manifests as multiple skin nodules, patchy hyperpigmentation, joint contractures and severe pain with movement. HFS shows some clinical overlap to Farber disease (FD), a recessive lysosomal storage disorder.</p> <p>Results: We here present the largest cohort of independent, genetically confirmed HFS cases reported to date: in 19 unrelated index patients, we identified ten distinct homozygous ANTXR2 mutations, three of which are novel frame-shift variants. The associated clinical data are consistent with the previous hypothesis of non-truncating variants in the terminal exons 13-17 to confer rather mild phenotypes. The novel observation of gender-dependent disease manifestation in our cohort received support from a meta-analysis of all previously published cases. Untargeted blood-based metabolomics revealed patient samples to be biochemically distinct from control samples. Numerous potential HFS biomarker metabolites could thus be identified. We also found metabolomics profiles of HFS patients to highly overlap with those from FD patients.</p> <p>Conclusions: Our study extends the mutational spectrum for HFS, suggests gender-dependency of manifestation, and provides pilot metabolomics data for biomarker identification and a better pathomechanistic understanding of the disorder.</p>
<b>Corresponding Author:</b>	Claudia Cozma Centogene AG GERMANY
<b>Corresponding Author Secondary Information:</b>	
<b>Corresponding Author's Institution:</b>	Centogene AG
<b>Corresponding Author's Secondary Institution:</b>	
<b>First Author:</b>	Claudia Cozma
<b>First Author Secondary Information:</b>	
<b>Order of Authors:</b>	Claudia Cozma Marina Hovakimyan Marius-Ionu Iuracu Nawal Makhseed Laila A. Selim Amal M. Alhashem Tawfeg Ben-Omran Iman G. Mahmoud Nihal M. Al Menabawy Mariam Al-Mureikhi

[Click here to view linked References](#)submission as article type *Research* to *Orphanet Journal of Rare Diseases*

**Genetic, clinical and biochemical characterization of a large cohort of patients with  
hyaline fibromatosis syndrome**

Claudia Cozma<sup>1</sup>, Marina Hovakimyan<sup>1</sup>, Marius-Ionuț Iurașcu<sup>1</sup>, Nawal Makhseed<sup>2</sup>, Laila A. Selim<sup>3</sup>, Amal M. Alhashem<sup>4,5</sup>, Tawfeg Ben-Omran<sup>6</sup>, Iman G. Mahmoud<sup>3</sup>, Nihal M. Al Menabawy<sup>3</sup>, Mariam Al-Mureikhi<sup>6</sup>, Magi Martin<sup>6</sup>, Laura Demuth<sup>1</sup>, Zafer Yüksel<sup>1</sup>, Christian Beetz<sup>1</sup>, Peter Bauer<sup>1</sup>, Arndt Rolfs<sup>1,7</sup>

<sup>1</sup> Centogene AG, Rostock, Germany

<sup>2</sup> Department of Pediatrics, Jahra Hospital, Ministry of Health, Jahra City, Kuwait

<sup>3</sup> Kasr Al Ainy School of Medicine, Division of Neurology and Metabolism, Cairo University Children Hospital, Cairo, Egypt

<sup>4</sup> Prince Sultan Military Medical City, Pediatrics, Riyadh, Saudi Arabia

<sup>5</sup> Alfaisal University, Riyadh, Saudi Arabia

<sup>6</sup> Division of Clinical and Metabolic Genetics, Department of Pediatrics, Hamad Medical Corporation, Doha, Qatar

<sup>7</sup> Rostock Medical University, Rostock, Germany

to whom correspondence should be addressed:

Claudia Cozma, Centogene AG, Am Strande 7, 18057 Rostock, Germany; Email:

claudia.cozma@centogene.com; phone: +49 381 80113527; fax: +49 381 80113401

Email addresses of all authors:

1  
2 Claudia Cozma : Claudia.cozma@centogene.com  
3

4 Marina Hovakimyan: Marina.hovakimyan@centogene.com  
5

6 Marius-Ionuț Iurașcu: Marius.iurascu@centogene.com  
7

8 Nawal Makhseed: nmakhseed@yahoo.com  
9

10 Laila A. Selim: lselim83@gmail.com  
11

12 Amal M. Alhashem: aalhashem@psmmc.med.sa  
13

14 Tawfeg Ben-Omran: tawben11@hotmail.com  
15

16 Iman G. Mahmoud: imangamal@yahoo.com  
17

18 Nihal M. Al Menabawy: nihaal\_magdi@hotmail.com  
19

20 Mariam Al-Mureikhi: MAlmureikhi@hamad.qa  
21

22 Magi Martin: MMartin@hamad.qa  
23

24 Laura Demuth: Laura.demuth@centogene.com  
25

26 Zafer Yüksel: zafush@yahoo.com  
27

28 Christian Beetz: Christian.beetz@centogene.com  
29

30 Peter Bauer: Peter.bauer@centogene.com  
31

32 Arndt Rolfs: Arndt.rolfs@centogene.com  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

## Abstract

**Background:** Hyaline fibromatosis syndrome (HFS) is a rare clinical condition in which bi-allelic variants in *ANTXR2* are associated with extracellular hyaline deposits. It manifests as multiple skin nodules, patchy hyperpigmentation, joint contractures and severe pain with movement. HFS shows some clinical overlap to Farber disease (FD), a recessive lysosomal storage disorder.

**Results:** We here present the largest cohort of independent, genetically confirmed HFS cases reported to date: in 19 unrelated index patients, we identified ten distinct homozygous *ANTXR2* mutations, three of which are novel frame-shift variants. The associated clinical data are consistent with the previous hypothesis of non-truncating variants in the terminal exons 13-17 to confer rather mild phenotypes. The novel observation of gender-dependent disease manifestation in our cohort received support from a meta-analysis of all previously published cases. Untargeted blood-based metabolomics revealed patient samples to be biochemically distinct from control samples. Numerous potential HFS biomarker metabolites could thus be identified. We also found metabolomics profiles of HFS patients to highly overlap with those from FD patients.

**Conclusions:** Our study extends the mutational spectrum for HFS, suggests gender-dependency of manifestation, and provides pilot metabolomics data for biomarker identification and a better pathomechanistic understanding of the disorder.

**Keywords:** *ANTXR2*, biomarker, Farber disease, genotype-phenotype correlation, hyaline fibromatosis syndrome

## Background

1  
2  
3 Hyaline fibromatosis syndrome (HFS, MIM #22860) is characterized by the accumulation of  
4  
5 clear (hyaline) substance in body tissues. Such noncancerous masses may grow under the skin  
6  
7 and the gums resulting in painful bumps/nodules and gingival hypertrophy, respectively. Joint  
8  
9 stiffness and deformities are frequent, and the skin covering the joints is often hyperpigmented.  
10  
11 Nodules that form in the intestine result in severe diarrhea and cachexia. Patients may come to  
12  
13 clinical attention from birth to late childhood. The most common initial symptoms include  
14  
15 extreme pain at minimal handling and progressive joint contractures (1). An early onset, more  
16  
17 severe, and usually fatal form termed infantile systemic hyalinosis (ISH) had long been  
18  
19 differentiated from a later onset and less severe form termed juvenile hyaline fibromatosis  
20  
21 (JHF) (2). The finding of a shared genetic background, however, eventually resulted in the  
22  
23 suggestion to use the umbrella term HFS along with a three-partite clinical grading scheme  
24  
25 (mild vs. moderate vs. severe) (3). A refinement to four severity grades was proposed more  
26  
27 recently (4).

28  
29  
30  
31  
32  
33  
34  
35 HFS is a recessive, genetically homogeneous disorder; it is caused by bi-allelic variants in  
36  
37 *ANTXR2* (5) (6). Approximately 100 genetically confirmed patients which carry a total of 46  
38  
39 distinct HFS-associated variants have been published to date [The Human Gene Mutation  
40  
41 Database at <http://www.hgmd.cf.ac.uk>]. Most frequent are missense alterations (n=19), but  
42  
43 clearly inactivating alleles (3 x nonsense, 9 x splice site, 13 x frameshift, 2 x large deletions)  
44  
45 collectively predominate. With the exception of a mutational hotspot at c.1072\_1076,  
46  
47 pathogenic variants are more or less equally distributed over the coding sequence (7).

48  
49  
50  
51  
52 One of the two initial papers on *ANTXR2* mutations in HFS suggested that non-truncating  
53  
54 variants which affect the protein's C-terminus (encoded by exons 13-17) are associated with  
55  
56 comparatively late disease onset and a rather benign disease course (5). Two subsequent meta-  
57  
58  
59  
60  
61  
62  
63  
64  
65

1 analyses found additional support for this hypothesis (7) (8). The overall rarity of HFS,  
2 however, has hampered the search for further genotype-phenotype correlations.  
3

4  
5 The *ANTXR2* gene had initially been designated *CMG2* (capillary morphogenesis gene 2), and  
6  
7 this was based on the observation of elevated expression in vein endothelial cells induced to  
8  
9 undergo capillary formation (9). The subsequent finding of the encoded protein to serve as a  
10  
11 receptor for the bacterial anthrax toxin resulted in the renaming to *ANTXR2* (anthrax toxin  
12  
13 receptor 2) (10). The encoded *ANTXR2* protein interacts with several components of the  
14  
15 extracellular matrix (9). It has further been suggested to serve as a collagen receptor that  
16  
17 mediates collagen transport to lysosomes (11). Impaired degradative processes may therefore  
18  
19 contribute to the accumulation of hyaline material in HFS patients. The complete spectra of the  
20  
21 physiological and pathological roles of *ANTXR2*, however, remain to be defined.  
22  
23  
24  
25  
26

27  
28 HFS shows considerable clinical overlap to Farber disease (FD), an autosomal recessive,  
29  
30 infantile onset lysosomal storage disorder (12). FD is, in fact, the main differential diagnosis  
31  
32 for HFS, with painful and swollen joints as well as periarticular and subcutaneous nodules being  
33  
34 the most prominent shared symptoms (1) (13). FD is caused by mutations in *ASAHI*, the gene  
35  
36 encoding acid ceramidase (14). This lysosomal hydrolase catalyzes the breakdown of ceramides  
37  
38 into sphingosines and fatty acids (15). Applying a targeted metabolomics approach, we recently  
39  
40 identified ceramide C26:0 as a highly sensitive, blood-based biomarker for FD (16).  
41  
42 Conceptually similar studies in HFS are currently lacking.  
43  
44  
45  
46

47  
48 The present study is based on a large cohort of patients who presented with symptoms from the  
49  
50 HFS-FD clinical spectrum. We set out to genetically characterize this cohort, and to utilize it in  
51  
52 the search for novel genotype-phenotype correlations. We also applied an untargeted  
53  
54 metabolomics approach in order to gain preliminary biochemical insight into HFS.  
55  
56

## 57 **Results**

58  
59  
60  
61 Nineteen unrelated index cases are homozygous for known or novel variants in *ANTXR2*  
62  
63  
64  
65

1 Sanger sequencing of the *ANTXR2* gene, as requested for nine patients that had received a  
 2 clinical diagnosis of HFS, readily identified a single homozygous variant in eight cases. In the  
 3  
 4 remaining sample, no sequence aberrations were found, but attempts to amplify exons 15 and  
 5  
 6 16 repeatedly failed. This finding suggests presence of a large homozygous deletion which  
 7  
 8 encompasses *ANTXR2* exons 15 and 16. Five additional patients, for which extended Sanger  
 9  
 10 sequencing was initiated following negative *ASAH1* screening, were also found positive for  
 11  
 12 homozygous *ANTXR2* variants. Finally, in five patients for which WES had been requested and  
 13  
 14 which showed a suggestive phenotype, homozygous *ANTXR2* variants were identified. For four  
 15  
 16 of the 19 index patients, material from two to six unaffected family members was available.  
 17  
 18 These were all found to not carry the familial variant or to be heterozygous carriers (true for all  
 19  
 20 available parental samples). All 19 patients thus received a genetic diagnosis of *ANTXR2*-  
 21  
 22 related HFS (Table 1).  
 23  
 24  
 25  
 26  
 27

28  
 29 In total, there were 10 distinct variants, seven of which have been described previously (Figure  
 30  
 31 1A,B; Table 2). By far the most frequently observed variant was c.1074delT (identified 6x),  
 32  
 33 followed by c.134T>C (4x) and c.720delT (2x). Three distinct variants (c.1073dupC,  
 34  
 35 c.1073delC and c.1074delT) affected a specific dinucleotide in exon 13, whereas the other  
 36  
 37 variants appeared more or less evenly distributed over the coding sequence (Figure 1A). Six of  
 38  
 39 the ten variants were frameshift variants, two were missense, and one each was a nonsense  
 40  
 41 variant and a large in-frame deletion, respectively (Table 2).  
 42  
 43  
 44  
 45  
 46

#### 47 Clinical presentation of *ANTXR2*-related HFS may be gender dependent

48  
 49 Clinical information had been provided for 15 of the 19 patients; Table 1 summarizes these  
 50  
 51 findings. The primary phenotypic observations were available as only rudimentary notions for  
 52  
 53 some patients, but in much greater detail for others. This fact precluded a well-founded search  
 54  
 55 for genotype-phenotype correlations. In order to still enable testing for associations, we focused  
 56  
 57 on age at referral/manifestation. We further stratified patients according to the type of variant  
 58  
 59  
 60  
 61  
 62  
 63  
 64  
 65

1 (truncating vs. non-truncating) and gender, and considered whether the variant is in-frame and  
2 in exons 13-17 or not (compare introduction and see Supplementary Table 1). While there was  
3  
4 no evidence for an impact of the type of variant, the single in-frame variant localizing to exons  
5  
6 13-17 was associated with the maximum age at referral. Moreover, female patients were found  
7  
8 to be significantly older than male patients at referral (Figure 2). As the latter finding was  
9  
10 unexpected and as we also noticed a (non-significant) male predominance in our cohort (13  
11  
12 males vs. 6 females), we analyzed gender of all genetically confirmed HFS patients as reported  
13  
14 in the literature (Supplementary Table 2). We did not observe male predominance (36 males  
15  
16 vs. 36 females), but there was a trend for males to more frequently being diagnosed with ISH  
17  
18 rather than with JFH (19 male ISH plus 6 male JFH vs. 14 female ISH plus 13 female JFH;  
19  
20  $p=0.064$ , one-sided Fisher's Exact Test).  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65



### Metabolomic profiles from HFS patients are inherently different from those of controls

1  
2  
3 Metabolomic profiling of samples from 11 HFS patients and 12 controls identified a total of  
4  
5 4,978 compounds that met our detection criteria as regards quality and quantity. We first  
6  
7 analyzed these data in an unsupervised manner. Principal component analysis (PCA)  
8  
9 completely separated both types of samples, and this was mainly due to principal component 1  
10  
11 which explains 33.9% of the overall variability (Figure 3A). Similarly, hierarchical clustering  
12  
13 showed that most HFS patient samples are closer related to each other than to any of the control  
14  
15 samples (Figure 3B). These initial observations indicated that the metabolomics data are highly  
16  
17 structured, and that this structure is largely dictated by clinical status.  
18  
19  
20  
21

### Numerous individual compounds flag HFS patient samples with 100% sensitivity

22  
23  
24  
25 Given the above finding of a strong overall difference between samples from patients vs. from  
26  
27 controls, we next aimed at identifying the very compounds that confer this difference.  
28  
29 Considering the biomarker aspect of our study, we not simply searched for compounds with  
30  
31 significantly differing values, but for compounds for which the range of values in patients does  
32  
33 not overlap with the range in controls. A total of 181 such compounds were identified. 135 of  
34  
35 these (75%) were decreased in patients, while 46 (25%) were increased (Figure 4A).  
36  
37  
38  
39

40  
41 The identity was unknown for 112 of the 181 candidate compounds, but many of these showed  
42  
43 very large differences between patients and controls (e.g. Figure 4B<sub>1</sub>). For the remaining 69  
44  
45 compounds, mass and charge enabled deducing a likely identity. The corresponding list  
46  
47 contained several ceramides (e.g. Figure 4B<sub>2</sub>) and sphingomyelins (e.g. Figure 4B<sub>3</sub>), but also  
48  
49 di- and triglycerides (not shown). Ceramide 26:0, previously shown by us to be increased in a  
50  
51 10 of 10 FD patients (16), was not amongst the fully sensitive biomarker candidates, but the  
52  
53 values in HFS patients were significantly higher than in controls ( $p=0.01$ , two-sided Student's  
54  
55 T-test) (Figure 4B<sub>4</sub>).  
56  
57  
58  
59

### HFS samples and FD samples are biochemically highly similar

1 Based on the clinical overlap between HFS and FD, and on finding ceramide 26:0 to be  
 2 increased in both conditions, we aimed at comparing the metabolomics profiles from HFS  
 3 patients and FD patients. Applying our predefined quality and quantity criteria, 5,248  
 4 compounds survived filtering. Principal components 1 and 2 in PCA (collectively explaining  
 5 52.8% of the overall variability) revealed the samples from both types of patients to collectively  
 6 define a larger entity which is rather diverse, but clearly distinct from control samples (Figure  
 7 5A; compare Figure 3A). Unsupervised hierarchical clustering confirmed this observation, and,  
 8 in addition, revealed evidence for disease-specificity of the metabolomics profiles (Figure 5B).  
 9 We finally defined all compounds for which values differed significantly from control values  
 10 in HFS patients and in FD patients. We thereby identified 436 compounds for HFS and 268  
 11 compounds for FD. 81 compounds were shared, and this finding is highly significant ( $p=7 \times 10^{-18}$ ,  
 12 two-sided Fisher's Exact Test) (Figure 5C). Moreover, the direction of change was the same  
 13 in HFS and FD samples for all 81 compounds (Figure 5D<sub>1</sub>). This was also true for every  
 14 compound which differed significantly from controls in only HFS samples (Figure 5D<sub>2</sub>) or in  
 15 only FD samples (Figure 5D<sub>3</sub>).

## 36 Discussion

37 HFS is a very rare disorder. Most previous clinical-genetic studies have therefore been able to  
 38 present one or a few cases only. With a size of  $n=19$ , our cohort significantly increases the  
 39 number of known independent patients with genetically confirmed HFS from 74 to 93 (compare  
 40 Supplementary Table 2). Together with the pioneering paper by Hanks et al. (5), in which 18  
 41 families were described, our study thereby represents the largest genetic report on HFS.

42 All of our patients were found to be homozygous for pathogenic *ANTXR2* variants, while 21%  
 43 of previously published cases were compound heterozygous (8). Considering our cohort to  
 44 contain many consanguineous families (Table 1), and to generally derive from regions with a  
 45 high degree of consanguineous marriages (Table 2), the above observation is not surprising.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

Geographic origin may also serve to explain recurrent identification of certain variants (Table 2). This is probably true for c.1074delC, which was present in six of our patients and has previously been associated with a specific haplotype (17). There is evidence for further founder variants, but also for *ANTXR2* mutational hotspots (5). A more detailed investigation of this issue in our cases, however, was beyond the scope of the diagnosis-focused concept of the present study.

Three of the ten variants we observed have not been reported previously (Figure 1A, Table 2). Our genetic findings thereby increase the number of known pathogenic *ANTXR2* variants to 49 [The Human Gene Mutation Database at <http://www.hgmd.cf.ac.uk>]. All three novel variants are deletions of single nucleotides in rather 5'-situated or central exons, and are therefore predicted to trigger nonsense-mediated decay (18). They thus represent bona fide loss-of-function variants, supporting the hypothesis of HFS to be mediated by absence of *ANTXR2* or complete functional inactivation (19).

The phenotypes of all patients for which clinical information was available were consistent with the well-known, though wide-ranging spectrum of manifestations of HFS (Table 1) (1). Pertinent information, together with the comparatively large size of our cohort enabled us to analyze potential clinical correlations. The only corresponding finding from previous studies was that variants which affect the protein's cytoplasmic tail (encoded by the terminal exons 13-17) and are predicted to not result in mRNA instability are associated with an overall milder disease and a later onset (5) (7) (8). As there was only one patient with such a variant in our cohort (Supplementary Table 1), a formal statistical analysis was not possible. However, the fact that this patient was >20 years and alive at referral strongly supports a comparatively mild nature of the corresponding in-frame deletion (Figure 2). We next stratified patients more generally according to the type of variant. This was based on the observation of non-truncating variants to be less detrimental than truncating variants in some genes (e.g. ref. 20). We did,

1 however, not find evidence for an impact of the type of *ANTXR2* variant on age at onset of HFS  
 2 (Figure 2). When finally considering the gender of patients, we noticed considerable male  
 3  
 4 predominance in our cohort, and found our male patients to be significantly younger at referral  
 5  
 6 (Figure 2). Given the geographic background of our cohort (Table 2), this observation may  
 7  
 8 partially be explained by cultural factors that favor males over females in access to health care  
 9  
 10 (21). We therefore initiated an exhaustive literature analysis. Though age-related data could not  
 11  
 12 be compiled in a sufficiently uniform manner, there was a trend for females to more often being  
 13  
 14 diagnosed with JFH rather than ISH(Supplementary Table 2), which indicates an overall milder  
 15  
 16 manifestation and later onset (3). Together with the fact that there was no evidence for male  
 17  
 18 predominance amongst previously published cases (Supplementary Table 2) (8), this findings  
 19  
 20 argues against a major impact of the above cultural factors. A gender-dependency of the clinical  
 21  
 22 consequences of *ANTXR2* mutations may thus be real. Though very rare, the phenomenon of  
 23  
 24 gender-specific disease manifestation has been reported for other autosomal genes (e.g. refs.  
 25  
 26 22-24). Understanding its pathological basis in HFS may eventually result in hitherto  
 27  
 28 unexplored therapeutic options.  
 29  
 30  
 31  
 32  
 33  
 34  
 35  
 36

37 As far as we are aware, our biochemical characterization of samples from HFS patients is the  
 38  
 39 first pertinent effort published to date. It was facilitated by both the size of our HFS cohort and  
 40  
 41 the availability of DBS samples. Given the lack of hypotheses about the impact of *ANTXR2*  
 42  
 43 variants on certain blood metabolites, we had chosen an untargeted approach. Unsupervised  
 44  
 45 analyses revealed that patient metabolomes are inherently different from control metabolomes  
 46  
 47 (Figure 3). Part of this overall difference, though, may be related to the lack of age- and gender-  
 48  
 49 matching in our study. Indeed, metabolomics profiles have been shown to both change over  
 50  
 51 time and differ between genders (25) (26) (27). Ranges of values in corresponding studies,  
 52  
 53 however, highly overlap and mean fold-changes rarely exceed 3, and this is in stark contrast to  
 54  
 55 what is observed for our set of data (Figure 4). Another factor that may conceptually affect a  
 56  
 57  
 58  
 59  
 60  
 61  
 62  
 63  
 64  
 65

1 comparison between patient and control metabolomes is medication (28). For HFS, however,  
2 nonsteroidal anti-inflammatory drugs and opiates represent the only potentially shared drugs  
3  
4 (1), and these are not expected to have major influences. We thus considered the majority of  
5  
6 the metabolic differences to be truly related to clinical/mutational status.  
7  
8  
9

10 Our attempt to define potential metabolomics biomarkers for HFS resulted in a list of 181  
11  
12 candidate compounds that are associated with maximum discriminatory power (i.e. 100%  
13  
14 sensitivity) for our patient vs. control cohorts. Though the inclusion of larger numbers of  
15  
16 samples can be expected to result in a reduced list and in a drop in sensitivity, this observation  
17  
18 of our pilot study is highly promising. In addition to the primarily diagnostic aspect addressed  
19  
20 here, some of the compounds may eventually turn out to be of further relevance, e.g. for  
21  
22 monitoring disease progression and drug response, for a stratification of patients, and/or for a  
23  
24 better understanding of the underlying pathology (29).  
25  
26  
27  
28  
29

30 A phenotypic overlap of HFS and FD has long been recognized (1), and our clinical-genetic  
31  
32 findings (Table 1) re-inforce the notion that a primary clinical diagnosis of FD may need to be  
33  
34 corrected to HFS upon genetic work-up (e.g. ref. 30). With FD resulting from an enzyme  
35  
36 deficiency (31) and HFS being due to inactivation of what is likely an extracellular collagen  
37  
38 receptor (11), additional analogies at the level of pathobiochemistry would not necessarily be  
39  
40 expected. Our comparative analysis still suggested that the phenotypic similarity of HFS and  
41  
42 FD extends to the blood metabolomics signatures (Figure 5). Future studies will be needed to  
43  
44 see whether this observation is due to a sharing of the primary cellular defect(s) and, thus, to  
45  
46 common potential targets for therapeutic interventions.  
47  
48  
49  
50  
51

## 52 **Conclusions**

53  
54  
55 The present paper reports on a comparatively large number of previously unreported patients  
56  
57 with HFS, and thereby significantly extends the mutational and clinical spectra associated with  
58  
59 this disease. A previously suggested genotype-phenotype correlation received further support,  
60  
61  
62  
63  
64  
65

1 and gender-dependency of manifestation is suggested as a previously unrecognized  
2 phenomenon. The additional metabolomics findings represent a promising basis for the  
3 development of HFS-specific biomarkers, and for understanding the pathophysiology of the  
4 disease. Our study thereby provides valuable novel insights into this very rare genetic condition.  
5  
6  
7  
8  
9

## 10 **Methods**

### 11 Patients

12  
13 The present study enrolled 19 unrelated patients referred for genetic diagnostic workup of  
14 presumably congenital phenotypes to Centogene AG. Nine of them had received an expert  
15 clinical diagnosis of HFS, and targeted *ANTXR2* sequencing was requested. For five patients,  
16 the initial genetic diagnostic request had been targeted *ASAH1* sequencing based on a clinical  
17 suspicion of FD. Whole exome sequencing (WES) was requested for the remaining five patients  
18 (Table 1). For a subset of the above index cases, samples from unaffected family members were  
19 provided, too. The most frequent region of origin was the Middle East, followed by Africa,  
20 Latin American and Asia (compare Table 2). For metabolomic profiling, five patients with  
21 genetically confirmed FD and 12 healthy controls were included (16).  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37

### 38 DNA preparation

39  
40 Samples were provided as ready-to-use DNA, EDTA blood, or as dried blood spots (DBSs) on  
41 filter cards (CentoCard®, Centogene, Germany). Extraction from the blood-based samples  
42 utilized QIA Symphony instruments in combination with reagents and kits as recommended by  
43 the manufacturer (Qiagen, Hilden, Germany).  
44  
45  
46  
47  
48  
49  
50

### 51 *ANTXR2* variant screening

52  
53 The coding sequence of *ANTXR2* (NM\_058172.5; NP\_477520.2) including at least 50 bp of  
54 adjacent untranslated regions or intronic sequences was amplified exon-wise from genomic  
55 DNA (primers available upon request). PCR-products were extracted from agarose gels,  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

1 purified according to standard procedures, and sequenced from both sides on a 3730xl  
2 sequencer (Thermo Fisher Scientific, Waltham, MA).  
3

#### 4 Metabolomic profiling

5  
6  
7  
8 Three DBS punches of 3.2 mm in diameter were prepared from filtercards using a DBS puncher  
9 (Perkin Elmer LAS, Germany), and collected into 2.2 ml round bottom tubes (Eppendorf,  
10 Germany). Extraction was performed by adding 50 µL extraction solution (DMSO:H<sub>2</sub>O, 1:1)  
11 and 100 µL internal standard solution (lyso-Gb2, Matreya LLC, USA, 200 ng/mL in ethanol).  
12  
13 After a brief vortex-mixing, the tubes were shaken (700 rpm) at 37°C for 30 min and then  
14  
15 sonicated at maximum power for 1 min. All liquid was subsequently transferred to an AcroPrep  
16  
17 Filter Plate with PTFE membrane (PALL, Germany) placed on a 96 well V-shape bottom plate  
18  
19 (VWR, Germany). To remove solid particles, samples were filtrated by centrifugation at 3.500  
20  
21 rpm for 5 min.  
22  
23

24  
25  
26  
27  
28  
29 Mass spectrometric (MS) analysis was performed on a Waters Acquity i class UPLC (Waters,  
30  
31 UK) coupled with a Vion IMS-QToF mass spectrometer (Waters, UK). Chromatographic run  
32  
33 was performed on a Kinetex EVO C18 column (Phenomenex, Germany) with a gradient from  
34  
35 0 % to 100 % organic solvent (50 mM formic acid in acetonitrile:methanol, 1:1, v:v). Mass  
36  
37 spectrometric acquisition was made using the following parameters: analyzer mode -  
38  
39 sensitivity, MS mode - High definition MSE, capillary voltage - 1.2 kV, source temperature -  
40  
41 150°C, desolvation temperature - 600°C, desolvation gas - 1000 L/h, cone gag - 50 L/h, low  
42  
43 collision energy - 6 eV, high collision energy ramp: 20-40 eV, scan mass: 50 - 1000 m/z, scan  
44  
45 time - 0.5 s.  
46  
47  
48  
49  
50

51  
52 10 µL samples were injected and an HDMSE analysis method was used. The acquisition was  
53  
54 done using the Unifi software (Waters, UK) and the results exported as a Unifi export file (.uep).  
55  
56 The results were imported in the Progenesis QI software (Nonlinear Dynamics, UK) for  
57  
58 statistical interpretation. From the list of identified compounds, only those with significant  
59  
60  
61  
62  
63  
64  
65

1 difference between the groups were selected for further use. Targeted mass spectrometry-based  
2 screening for the levels of ceramide C26:0 in DBSs was performed as described in detail  
3  
4 previously (16).  
5

#### 6 Normalization, filtering and analysis of metabolomics data

7  
8  
9  
10 Raw abundances as detected by untargeted MS were normalized using default settings in  
11  
12 Progenesis. Compounds with a charge of  $> 5$  and a mass-to-charge ratio ( $m/z$ )  $< 179$  were  
13  
14 removed (quality filters). For comparative analyses, only compounds with a median normalized  
15  
16 abundance of  $>100$  counts relative to the reference compound in at least one of the groups under  
17  
18 consideration were retained (quantity filter).  
19  
20  
21

22  
23 Normalized and filtered abundances were transformed into CSV files, and uploaded into the  
24  
25 ‘Statistical Analysis’ tool-box of MetaboAnalyst 4.0 at <http://www.metaboanalyst.ca> (32).  
26  
27  
28 Principal component analysis was performed using default settings. Dendrograms were derived  
29  
30 using distance measure ‘Spearman’ and clustering algorithm ‘Single’. Distributions and ranges  
31  
32 for values were visualized by generating heat-maps with enforced sample grouping.  
33  
34

#### 35 **Declarations**

##### 36 Ethics approval and consent to participate

37  
38  
39  
40  
41 In compliance with the Declaration of Helsinki, informed written consent for genetic and  
42  
43 biochemical analyses was obtained for all samples. The study was approved by the Ethical  
44  
45 Committee of Rostock University (#A2017-0083).  
46  
47  
48

##### 49 Consent for publication

50  
51  
52 Not applicable.  
53  
54

##### 55 Availability of data and materials

56  
57  
58 The datasets generated and/or analyzed during the current study are available from the  
59  
60 corresponding author on reasonable request.  
61  
62  
63  
64  
65



### Competing interests

CC, MH, MI, LD, CB, PB and AR are employees of Centogene AG; ZY is a former employee of Centogene AG. The other authors declare that they have no competing interests.

### Funding

There was no specific funding for the study.

### Author's contributions

NM, LS, AA, TB, IM, NA, MA and MM saw and clinically diagnosed the patients, and collected samples. CC, MH MI, LD and ZY performed experiments and compiled all primary data. CC, MH, MI, CB, PB and AR analyzed and interpreted the data. CC, MH, CB, PB and AR drafted the manuscript. CC, PB and AR initiated and planned the study. All authors were involved in revising the manuscript, gave final approval of the version to be published, participated sufficiently in the work to take public responsibility for appropriate portions of the content, and agreed to be accountable for all aspects of their work.

### Acknowledgements

The authors thank the patients and their families for participating in the study.

1  
2 **References**  
3  
4

- 5 1. Shieh JTC, Hoyme HE, Arbour LT. Hyalinosis, Inherited Systemic. In: Adam MP,  
6 Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Stephens K, et al., editors.  
7 GeneReviews((R)). Seattle (WA)1993.  
8  
9  
10  
11  
12 2. Landing BH, Nadorra R. Infantile systemic hyalinosis: report of four cases of a  
13 disease, fatal in infancy, apparently different from juvenile systemic hyalinosis.  
14 *Pediatr Pathol.* 1986;6(1):55-79.  
15  
16  
17  
18  
19  
20 3. Nofal A, Sanad M, Assaf M, Nofal E, Nassar A, Almokadem S, et al. Juvenile hyaline  
21 fibromatosis and infantile systemic hyalinosis: a unifying term and a proposed grading  
22 system. *J Am Acad Dermatol.* 2009;61(4):695-700.  
23  
24  
25  
26  
27  
28 3. Denadai R, Raposo-Amaral CE, Bertola D, Kim C, Alonso N, Hart T, et al.  
29 Identification of 2 novel ANTXR2 mutations in patients with hyaline fibromatosis  
30 syndrome and proposal of a modified grading system. *Am J Med Genet Part A.*  
31 2012;158A(4):732-42.  
32  
33  
34  
35  
36  
37  
38  
39 5. Hanks S, Adams S, Douglas J, Arbour L, Atherton DJ, Balci S, et al. Mutations in the  
40 gene encoding capillary morphogenesis protein 2 cause juvenile hyaline fibromatosis  
41 and infantile systemic hyalinosis. *Am J Hum Genet.* 2003;73(4):791-800.  
42  
43  
44  
45  
46  
47 6. Dowling O, Difeo A, Ramirez MC, Tukel T, Narla G, Bonafe L, et al. Mutations in  
48 capillary morphogenesis gene-2 result in the allelic disorders juvenile hyaline  
49 fibromatosis and infantile systemic hyalinosis. *Am J Hum Genet.* 2003;73(4):957-66.  
50  
51  
52  
53  
54 7. Deuquet J, Lausch E, Superti-Furga A, van der Goot FG. The dark sides of capillary  
55 morphogenesis gene 2. *EMBO J.* 2012;31(1):3-13.  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

- 1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65  
8. Casas-Alba D, Martinez-Monseny A, Pino-Ramirez RM, Alsina L, Castejon E, Navarro-Vilarrubi S, et al. Hyaline fibromatosis syndrome: Clinical update and phenotype-genotype correlations. *Hum Mutat.* 2018;39(12):1752-63.
9. Bell SE, Mavila A, Salazar R, Bayless KJ, Kanagala S, Maxwell SA, et al. Differential gene expression during capillary morphogenesis in 3D collagen matrices: regulated expression of genes involved in basement membrane matrix assembly, cell cycle progression, cellular differentiation and G-protein signaling. *J Cell Sci.* 2001;114(Pt 15):2755-73.
10. Scobie HM, Rainey GJ, Bradley KA, Young JA. Human capillary morphogenesis protein 2 functions as an anthrax toxin receptor. *Proc Natl Acad Sci U S A.* 2003;100(9):5170-4.
11. Burgi J, Kunz B, Abrami L, Deuquet J, Piersigilli A, Scholl-Burgi S, et al. CMG2/ANTXR2 regulates extracellular collagen VI which accumulates in hyaline fibromatosis syndrome. *Nat Commun.* 2017;8:15861.
12. Ferreira CR, Gahl WA. Lysosomal storage diseases. *Transl Sci Rare Dis.* 2017;2(1-2):1-71.
13. Dymont DA, Bennett SAL, Medin JA, Levade T. ASAH1-Related Disorders. In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Stephens K, et al., editors. *GeneReviews*((R)). Seattle (WA)1993.
14. Koch J, Gartner S, Li CM, Quintern LE, Bernardo K, Levran O, et al. Molecular cloning and characterization of a full-length complementary DNA encoding human acid ceramidase. Identification Of the first molecular lesion causing Farber disease. *J Biol Chem.* 1996;271(51):33110-5.

15. Yu FPS, Amintas S, Levade T, Medin JA. Acid ceramidase deficiency: Farber disease and SMA-PME. *Orphanet J Rare Dis.* 2018;13(1):121.
16. Cozma C, Iurascu MI, Eichler S, Hovakimyan M, Brandau O, Zielke S, et al. C26-Ceramide as highly sensitive biomarker for the diagnosis of Farber Disease. *Sci Rep.* 2017;7(1):6149.
17. Youssefian L, Vahidnezhad H, Aghighi Y, Ziaee V, Zeinali S, Abiri M, et al. Hyaline Fibromatosis Syndrome: A Novel Mutation and Recurrent Founder Mutation in the CMG2/ANTXR2 Gene. *Acta Derm Venereol.* 2017;97(1):108-9.
18. Coban-Akdemir Z, White JJ, Song X, Jhangiani SN, Fatih JM, Gambin T, et al. Identifying Genes Whose Mutant Transcripts Cause Dominant Disease Traits by Potential Gain-of-Function Alleles. *Am J Hum Genet.* 2018;103(2):171-87.
19. Deuquet J, Abrami L, Difeo A, Ramirez MC, Martignetti JA, van der Goot FG. Systemic hyalinosis mutations in the CMG2 ectodomain leading to loss of function through retention in the endoplasmic reticulum. *Hum Mutat.* 2009;30(4):583-9.
20. Cornec-Le Gall E, Audrezet MP, Chen JM, Hourmant M, Morin MP, Perrichot R, et al. Type of PKD1 mutation influences renal outcome in ADPKD. *J Am Soc Nephrol.* 2013;24(6):1006-13.
21. Hesketh T, Xing ZW. Abnormal sex ratios in human populations: causes and consequences. *Proc Natl Acad Sci U S A.* 2006;103(36):13271-5.
22. Zatz M, Marie SK, Cerqueira A, Vainzof M, Pavanello RC, Passos-Bueno MR. The facioscapulohumeral muscular dystrophy (FSHD1) gene affects males more severely and more frequently than females. *Am J Med Genet.* 1998;77(2):155-61.

- 1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65
23. Mitne-Neto M, Kok F, Beetz C, Pessoa A, Bueno C, Graciani Z, et al. A multi-exonic SPG4 duplication underlies sex-dependent penetrance of hereditary spastic paraplegia in a large Brazilian pedigree. *Eur J Hum Genet.* 2007;15(12):1276-9.
  24. van Capelle CI, van der Meijden JC, van den Hout JM, Jaeken J, Baethmann M, Voit T, et al. Childhood Pompe disease: clinical spectrum and genotype in 31 patients. *Orphanet J Rare Dis.* 2016;11(1):65.
  25. Yu Z, Zhai G, Singmann P, He Y, Xu T, Prehn C, et al. Human serum metabolic profiles are age dependent. *Aging Cell.* 2012;11(6):960-7.
  26. Ishikawa M, Maekawa K, Saito K, Senoo Y, Urata M, Murayama M, et al. Plasma and serum lipidomics of healthy white adults shows characteristic profiles by subjects' gender and age. *PLoS One.* 2014;9(3):e91806.
  27. Hertel J, Friedrich N, Wittfeld K, Pietzner M, Budde K, Van der Auwera S, et al. Measuring Biological Age via Metabonomics: The Metabolic Age Score. *J Proteome Res.* 2016;15(2):400-10.
  28. Beger RD, Dunn W, Schmidt MA, Gross SS, Kirwan JA, Cascante M, et al. Metabolomics enables precision medicine: "A White Paper, Community Perspective". *Metabolomics.* 2016;12(10):149.
  29. Kim SH, Weiss C, Hoffmann U, Borggrefe M, Akin I, Behnes M. Advantages and Limitations of Current Biomarker Research: From Experimental Research to Clinical Application. *Curr Pharm Biotechnol.* 2017;18(6):445-55.
  30. Temtamy SA, Aglan MS, Otaify GA, Abdel-Hamid M, Ismail S, Makhrytanasis P, et al. Exome sequencing in the diagnosis of an atypical phenotype of infantile hyalinosis. *Middle East J Med Genet.* 2015;4:18-23.

- 1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65
31. Sugita M, Dulaney JT, Moser HW. Ceramidase deficiency in Farber's disease (lipogranulomatosis). *Science*. 1972;178(4065):1100-2.
32. Chong J, Soufan O, Li C, Caraus I, Li S, Bourque G, et al. MetaboAnalyst 4.0: towards more transparent and integrative metabolomics analysis. *Nucleic Acids Res*. 2018;46(W1):W486-W94.

## Figure legends

**Figure 1.** Results of *ANTXR2* mutation screening in 19 unrelated HFS patients. **(A)** Scheme of the 17-exon *ANTXR2* gene (coding parts of exons to scale). The exonic localisation as well as the number of independent observations (in parentheses) of pathogenic homozygous variant are indicated below the scheme. Novel variants are underlined. **(B)** Exemplary Sanger sequencing traces for patients that harbor one of the three novel variants each. RefSeq, reference sequence.

**Figure 2.** Potential clinical correlations. Age at referral for genetic workup is not associated with variant type, but may be influenced by variant localization, and correlates with gender (p-values according to the two-sided Mann-Whitney U-Test; n.a., not applicable).

**Figure 3.** Unsupervised analysis of all 4,978 compounds that met our detection criteria as regards quality and quantity upon comparative analysis of samples from HSF (in red) and control samples (in white). **(A)** Principal component analysis separates the majority of HSF patient samples from controls samples, and this is largely based on principal component 1. **(B)** Hierarchical clustering confirms that control samples are biochemically distinct from patient samples.

**Figure 4.** Potential HSF biomarkers. **(A)** Heat map visualizing all 181 compounds for which values in HSF samples do not overlap with values in control samples. Note that the majority of the compounds is decreased in patients. **(B)** Box-plots for selected compounds (control samples in white, HSF patient samples in red). Y-axes indicate fold-changes relative to the median for the control samples. (B<sub>2</sub>) Unknown compound with an m/z ratio of 417.300467 and a charge of 1; (B<sub>3</sub>) Ceramide Cer(d18:0/d22:0); (B<sub>4</sub>) Sphingomyelin SM(d18:1/d16:1). (B<sub>4</sub>) Ceramide C26:0.

**Figure 5.** Similarity of metabolic profiles from HSF and FD patients (HSF samples in red; FD samples in green; control samples in white). **(A)** Unsupervised PCA of all 5,248 compounds

1 that survived quality and quantity filters separates patient samples from controls samples, and  
2 this is largely based on principal component 1 (compare Figure 3A). **(B)** Unsupervised  
3 hierarchical clustering confirms that patient samples are biochemically distinct from control  
4 samples, and additionally suggests that HSF patients and FD patients differ in their overall  
5 metabolomic profiles. **(C)** To-scale scheme visualizing all 5,248 compounds (large square) in  
6 relation to the number of disease-specific compounds as specified. **(D)** Compound-specific  
7 fold changes (mean value for disease samples divided by mean value for control samples) for  
8 the 81 compounds which differed significantly from controls in both HSF and FD (D<sub>1</sub>), in  
9 only HSF (D<sub>2</sub>), or in only FD (D<sub>3</sub>).  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65



## Tables

**Table 1.** Genetic and clinical findings for the 19 unrelated patients analyzed by the present study.

Individual's ID	initial diagnostic request	gender	age at referral [months]	subcutaneous nodule	skin abnormalities	skeletal or muscle abnormalities	pain	joint involvement	coarse facies	visceral involvement	<i>ANTXR2</i> variants identified (all in homozygous state)
1013011	<i>ANTXR2</i>	male	8	+	+	+		+			c.1074delT
1019835	<i>ANTXR2</i>	female	248	+		+	+			+	c.1180-?_1428+?del
1030796	<i>ANTXR2</i>	male	12				n.r.				c.1074delT
1034217	<i>ANTXR2</i>	female	13				n.r.				c.1073dupC
1034651	<i>ANTXR2</i>	male	6				n.r.				c.134T>C
1062973	<i>ANTXR2</i>	male	8				n.r.				c.1074delT
1083931	WES	female	22			+		+	+		c.134T>C
1111097	<i>ANTXR2</i>	male	4				+	+			c.1074delT
1124610	<i>ANTXR2</i>	male	1	+	+		+	+			c.134T>C
1160661	<i>ANTXR2</i>	female	65	+	+	+		+		+	c.1294C>T
1167266	WES	female	16	+		+		+			c.652T>C
1175869	WES	male	3		+	+	+			+	c.720delT
1205436	ASAH1	male	5		+	+	+	+	+	+	c.720delT
1206223	ASAH1	male	18	+		+	+	+			c.994delC
1206224	WES	male	17	+		+	+	+	+		c.1073delC
1218829	ASAH1	male	10	+	+	+		+	+		c.1074delT
1219558	ASAH1	female	15	+		+		+			c.1074delT
1223185	WES	male	9			+		+	+	+	c.134T>C
1234238	ASAH1	male	8	+	+	+	+				c.51delC

n.r., not reported

**Table 2.** Novelty and geographic origin of *ANTXR2* variants identified by the present study.

variant	predicted consequence	times observed by present study	novel?	patient origin in present study	patient origin in previous studies <sup>†</sup>
3c.51delC	p.L19Cfs*56	1	yes	1 x Africa	-
c.134T>C	p.L45P	4	-	4 x Middle East	Middle East,
c.652T>C	p.C218R	1	-	1 x Middle East	Asia
c.720delT	p.S240Rfs*20	2	yes	2 x Middle East	-
c.994delC	p.L332Wfs*5	1	yes	1 x Africa	-
c.1073delC	p.P358Lfs*51	1	-	1 x Africa	Asia
c.1073dupC	p.A359Cfs*13	1	-	1 x Middle East	Middle East, Japan, North America, Latin America, Asia, Europe, unreported
c.1074delT	p.A359Hfs*50	6	-	5 x Middle East, 1 x Latin America	Middle East, Asia, Africa, Latin America, not reported
c.1294C>T	p.R432*	1	-	1 x Asia	Latin America, Asia, unreported
c.1180-?_1428+?del	p.V394_490del	1	-	1 x Middle East	Latin America

<sup>†</sup>for references see Supplementary Table 3









